Review of tirzepatide mechanism cites GLP-1 receptor affinity figure that differs from discovery paper
A new review of how tirzepatide works reports a receptor-affinity figure that differs from the drug's original discovery papers, a laboratory detail that does not change its approved uses.
A review published Nov. 6 in the journal Diabetes Therapy describes the mechanism of action of tirzepatide — the molecule in Mounjaro, approved for type 2 diabetes, and Zepbound, approved for weight management and obstructive sleep apnea — and states a GLP-1 receptor affinity figure that differs from the one in the drug's original discovery paper [1].
Tirzepatide is a single molecule that activates two receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. The review calls it first-in-class and dual-acting [1]. A C20 fatty diacid moiety on the molecule allows it to bind albumin, which prolongs its half-life and supports once-weekly dosing [1].
On receptor pharmacology, the review states that tirzepatide's affinity for the GLP-1 receptor is roughly 18- to 20-fold weaker than that of native GLP-1 [1]. The original discovery and receptor-occupancy papers for the drug reported a gap of roughly 5-fold [1]. Both figures come from laboratory binding studies. No explanation for the difference between the two figures has been reported.
The review also summarizes clinical milestones. The FDA approved tirzepatide for type 2 diabetes in 2022, for reducing excess weight in adults with obesity or overweight in 2023, and for moderate-to-severe obstructive sleep apnea in adults with obesity in 2024 [1]. It notes recent studies reporting benefits in metabolic dysfunction–associated steatohepatitis (MASH) and in heart failure with preserved ejection fraction in people with obesity, citing trials published in the New England Journal of Medicine in 2024 and 2025 [1]. Effects on cardiovascular outcomes in people with type 2 diabetes, described in a company press release, and on reducing illness and death in people with obesity or overweight who do not have diabetes remain under investigation, the review says [1].
The authors describe the paper as a review of previously conducted studies, so it does not present new trial results and required no ethics committee approval on that basis [1]. It covers tirzepatide and excludes other dual-agonist drugs still under study [1].
Why it matters for patients
Tirzepatide works through two receptors rather than one, and the review's account of how the drug engages the GLP-1 and GIP receptors is part of the explanation it offers for the clinical results seen in trials [1]. Both receptors are found in many tissues, including pancreatic beta cells, the gastrointestinal tract, the nervous system, the kidney, blood vessels and the heart, and the review says differences in where and how they act may contribute to the drug's clinical profile [1].
The affinity discrepancy is a laboratory measurement. The review does not suggest it changes tirzepatide's approved uses, its labeling or the results of the trials it summarizes, and it draws no clinical conclusion from the comparison [1]. Nothing in the review indicates patients should expect different effects from their medication because of the revised figure, and how any individual responds to a drug is not determined by a single binding measurement.
The practical picture the review provides is a list of approved uses and the trial evidence behind them: type 2 diabetes, weight management and obstructive sleep apnea are approved indications, while MASH, heart failure with preserved ejection fraction and cardiovascular outcomes are areas where studies have reported benefits or are still ongoing [1].
What happens next
The review flags two questions as unresolved: whether tirzepatide reduces cardiovascular events in people with type 2 diabetes, where it cites a company press release reporting cardiovascular protection in a head-to-head trial, and whether it reduces illness and death in people with obesity or overweight who do not have diabetes. The latter is being studied in a trial registered as NCT05556512 [1].
The review appears in Diabetes Therapy volume 17, pages 19–40 (2026) and was published online Nov. 6, 2025 [1].
Images from the sources
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.